Invicol

Invicol is an innovative, privately-held biotech company pioneering an in vivo approach to liquid biopsy. Its core technology, the BMProbe™, is a probe inserted into a patient's cubital vein to capture rare circulating cells from a significantly larger blood volume than standard blood draws, promising superior sensitivity for early cancer detection and cardiovascular monitoring. The company is in a pre-revenue, pre-clinical/development stage, advancing its platform through collaborative R&D projects with academic partners like Charité and Freie Universität Berlin, supported by German public grants. Invicol's success hinges on clinical validation, regulatory approval, and demonstrating a clear advantage over established in vitro diagnostic competitors.

The BMProbe™ is a minimally invasive medical device inserted into a patient's cubital vein for the in vivo isolation of rare circulating cells (e.g., Circulating Tumor Cells, Circulating Endothelial Cells) from a large volume of blood, followed by semi-automated cell retrieval and analysis.

Invicol competes in the liquid biopsy/diagnostics space dominated by companies using in vitro blood sample analysis (e.g., Guardant Health, Freenome, Biocept, Roche). Its key differentiator is the in vivo capture method, which promises higher sensitivity but faces adoption hurdles against the entrenched, less invasive standard of a blood draw.